383 related articles for article (PubMed ID: 15241826)
1. Prostate carcinoma among men with human immunodeficiency virus infection.
Crum NF; Spencer CR; Amling CL
Cancer; 2004 Jul; 101(2):294-9. PubMed ID: 15241826
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study.
Pantanowitz L; Bohac G; Cooley TP; Aboulafia D; Dezube BJ
BJU Int; 2008 Jun; 101(12):1519-23. PubMed ID: 18384640
[TBL] [Abstract][Full Text] [Related]
3. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
4. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
5. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
Price MM; Hamilton RJ; Robertson CN; Butts MC; Freedland SJ
Urology; 2008 May; 71(5):787-91. PubMed ID: 18267334
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.
Burgi A; Brodine S; Wegner S; Milazzo M; Wallace MR; Spooner K; Blazes DL; Agan BK; Armstrong A; Fraser S; Crum NF
Cancer; 2005 Oct; 104(7):1505-11. PubMed ID: 16104038
[TBL] [Abstract][Full Text] [Related]
7. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
8. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase.
Kristal AR; Chi C; Tangen CM; Goodman PJ; Etzioni R; Thompson IM
Cancer; 2006 Jan; 106(2):320-8. PubMed ID: 16342294
[TBL] [Abstract][Full Text] [Related]
9. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Freedland SJ; Mangold LA; Epstein JI; Partin AW
Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
[TBL] [Abstract][Full Text] [Related]
10. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
Ito K; Kubota Y; Yamamoto T; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
Cancer; 2001 Feb; 91(4):744-51. PubMed ID: 11241242
[TBL] [Abstract][Full Text] [Related]
11. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
13. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey.
Bunker CH; Patrick AL; Konety BR; Dhir R; Brufsky AM; Vivas CA; Becich MJ; Trump DL; Kuller LH
Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):726-9. PubMed ID: 12163325
[TBL] [Abstract][Full Text] [Related]
15. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
19. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
Eggener SE; Roehl KA; Catalona WJ
J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
[TBL] [Abstract][Full Text] [Related]
20. Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society.
Littrup PJ
Cancer; 1997 Nov; 80(9):1864-70. PubMed ID: 9351561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
